Quantum Genomics SA - ESG Rating & Company Profile powered by AI
If you work at Quantum Genomics SA and you wish to use your ESG rating, please get in touch. Scroll down to the bottom of this webpage for potential risks for Quantum Genomics SA based on industry, geography and marketcap. The webpage contains a zero-cost E,S&G assessment covering Quantum Genomics SA.
Quantum Genomics SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.1; made up of an environmental score of 2.0, social score of 5.3 and governance score of 8.0.
5.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 958 | Provectus Biopharmaceuticals Inc | 5.2 | High |
| 958 | Vectura Group Services Ltd | 5.2 | High |
| 999 | Quantum Genomics SA | 5.1 | High |
| 999 | Aequus Pharmaceuticals Inc | 5.1 | High |
| 999 | BioRestorative Therapies Inc | 5.1 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Quantum Genomics SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Quantum Genomics SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Quantum Genomics SA report the average age of the workforce?
Sign up for free to unlockDoes Quantum Genomics SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Quantum Genomics SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Quantum Genomics SA disclose cybersecurity risks?
Sign up for free to unlockDoes Quantum Genomics SA offer flexible work?
Sign up for free to unlockDoes Quantum Genomics SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Quantum Genomics SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Quantum Genomics SA conduct supply chain audits?
Sign up for free to unlockDoes Quantum Genomics SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Quantum Genomics SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Quantum Genomics SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Quantum Genomics SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Quantum Genomics SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Quantum Genomics SA disclose water use targets?
Sign up for free to unlockDoes Quantum Genomics SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Quantum Genomics SA have a product recall in the last two years?
Sign up for free to unlockDoes Quantum Genomics SA disclose incidents of discrimination?
Sign up for free to unlockDoes Quantum Genomics SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Quantum Genomics SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Quantum Genomics SA disclose parental leave metrics?
Sign up for free to unlockDoes Quantum Genomics SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Quantum Genomics SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Quantum Genomics SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Quantum Genomics SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Quantum Genomics SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Quantum Genomics SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Quantum Genomics SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Quantum Genomics SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Quantum Genomics SA disclose its waste policy?
Sign up for free to unlockDoes Quantum Genomics SA report according to TCFD requirements?
Sign up for free to unlockDoes Quantum Genomics SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Quantum Genomics SA disclose energy use targets?
Sign up for free to unlockDoes Quantum Genomics SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Quantum Genomics SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Quantum Genomics SA
These potential risks are based on the size, segment and geographies of the company.
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.